financetom
Business
financetom
/
Business
/
Tesla's China-made EV sales fall 6.6% y/y in May
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tesla's China-made EV sales fall 6.6% y/y in May
Jun 4, 2024 2:06 AM

BEIJING (Reuters) - U.S. automaker Tesla's sales of China-made electric vehicles dropped 6.6% from a year earlier to 72,573 units in May, data from the China Passenger Car Association (CPCA) showed on Tuesday.

Deliveries of China-made Model 3 and Model Y vehicles were up 16.7% from April.

Chinese rival BYD, with its Dynasty and Ocean series of EVs and plug-in hybrids, sold 330,488 passenger vehicles in May, up 38.2% year-on-year.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going On With 20/20 Biolabs Stock?
What's Going On With 20/20 Biolabs Stock?
Mar 24, 2026
Shares of 20/20 Biolabs, Inc. ( AIDX ) are trading lower Tuesday after the company announced that it entered into an exclusive U.S. technology license and access agreement with ROKIT Healthcare. 20/20 Biolabs ( AIDX ) stock is testing lower boundaries. What’s pressuring AIDX? Kidney Disease Algorithm To Be Integrated Into Biolabs’s Longevity Platform 20/20 will integrate ROKIT’s proprietary chronic kidney...
Spartan Delta Adopts a Shareholder-Rights Plan; Shares up 5.5%
Spartan Delta Adopts a Shareholder-Rights Plan; Shares up 5.5%
Mar 24, 2026
11:09 AM EDT, 03/24/2026 (MT Newswires) -- Spartan Delta ( DALXF ) on Tuesday said its board of directors adopted a shareholder-rights plan effective today. The Rights Plan is consistent with modern rights plans adopted by other Canadian public companies and has not been adopted in response to any specific proposal or intention to acquire control of Spartan, said the...
Gilead boosts immunology pipeline with over $2 billion buyout of Ouro Medicines
Gilead boosts immunology pipeline with over $2 billion buyout of Ouro Medicines
Mar 24, 2026
By Mariam Sunny March 23 (Reuters) - Gilead Sciences said on Monday it would buy privately held biotech firm Ouro Medicines in a deal worth more than $2 billion to expand its pipeline of immune disorder drugs. Best known for its HIV drugs, Gilead has been looking beyond its key areas for growth amid looming patent expiries and declining sales...
Amdocs Positioned to Win 'Intelligent Telco Era,' Oppenheimer Says
Amdocs Positioned to Win 'Intelligent Telco Era,' Oppenheimer Says
Mar 24, 2026
11:08 AM EDT, 03/24/2026 (MT Newswires) -- Amdocs ( DOX ) is positioned to win in the intelligent telco era given its track record of successful transformations and deep relationships with major industry players, Oppenheimer said. The company recently held a demonstration of its agentic operating system, or aOS, for telecom operators. Oppenheimer said aOS allows telcos to embed generative...
Copyright 2023-2026 - www.financetom.com All Rights Reserved